Adult Solid Neoplasm Completed Phase 1 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0029998 (Adult Solid Neoplasm)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01061749Selumetinib and Cixutumumab in Treating Patients With Advanced Solid MalignanciesTreatment